In This Article:
Tasso and Arup Laboratories have formed a collaboration for developing and ‘operationalising’ at-home, blood testing services, offering support to clinical research.
By combining Tasso’s clinical-grade blood collection technology with Arup’s testing services, which include more than 3,000 laboratory tests and test combinations, the partnership aims to expedite decentralised clinical research.
Arup performed validation for several assays, including for rheumatoid factor, high-sensitivity C-reactive protein, high-sensitivity DNA, and creatinine, for launching the collaboration.
These tests utilise capillary blood microsamples collected by Tasso's devices.
The partnership plans to expand its offerings with additional applications, as well as assays, throughout the year and beyond, following the completion of validation protocols.
Tasso's role in the partnership is pivotal, providing an end-to-end services platform that encompasses shipping and digital patient-facing solutions designed to ensure blood collection and logistics.
Arup innovation president Tracy George said: “By developing testing that is compatible with Tasso’s game-changing remote blood collection solutions, we will further increase participant access to clinical research.”
The medical directors at Arup, who are also faculty members at the University of Utah’s Spencer Fox Eccles School of Medicine Department of Pathology, bring their expertise to the test development and validation process.
Tasso co-founder and chief technology officer Erwin Berthier said: “Patient-centric testing solutions are needed to provide better access to clinical research and enable the development of personalised or predictive blood testing solutions.
“Tasso combining forces with Arup Laboratories, a trusted industry leader, enables us to provide gold standard remote testing solutions that remove barriers to adoption of decentralised testing.”
In June 2023, Arup Laboratories received the US Food and Drug Administration (FDA) approval for the AAV5 DetectCDx.
This companion diagnostic tool is crucial for identifying adult subjects eligible for treatment with Roctavian, a BioMarin Pharmaceutical-developed gene therapy.
"Tasso and Arup to develop blood testing services for clinical research" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.